Article · 2 Jun 2026
Conference abstract
Production of therapeutically relevant lentiviral vectors for clinical studies
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The successful genetic engineering of patient-specific T cells with lentiviral vectors (LVV) expressing, e.g., chimeric antigen receptors for late phase clinical trials and beyond, requires the large-scale manufacturing of high-titer vector stocks. Their mass production remains a challenge and limits their potential therapeutic use, requiring robust, scalable and regulatorycompliant processes for industrial vector production. The state-of-the-art production of lentiviral vectors is based on 10 to 40 layer cell factories transiently transfected in the presence of serum. This manufacturing process is extremely limited by its labor intensity, open-system handling operations and its requirement for significant incubator space, plus costs and patient risk due to the presence of serum. To circumvent these limitations, this study aims to develop a stable and serum-free process to produce lentiviral vectors with PEI-mediated transfection. In addition, this study also focuses on the development of a production system not only using a GFP marker but also therapeutically relevant transgenes to overcome the limitations of GFP as process prediction model. Three different cell lines (HEK 293, HEK 293T, HEK 293FT) were investigated concerning their productivity of LVV and their growing behavior in the in-house serum free medium TransMACS. As part of this, a design of experiment was used to investigate the optimal conditions for PEI/DNA-transfection. Furthermore, this statistical approach was used to identify an ideal ratio between the four 3rd generation plasmids (transfer plasmid, envelope plasmid, packaging plasmids). In addition, several different transfection enhancers were investigated concerning their enhancing effects on productivity, comparing HEK cultures producing LVV encoding for different transfer genes.
Keywords
Subjects
Genetics & Molecular BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Stem Cell Research & Therapy.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Stem Cell Research & Therapy
- SubjectGenetics & Molecular Biology
- BylineArticles whose byline prints “Johann-Christoph Dettmann”
- BylineArticles whose byline prints “Martin Meyer”
- BylineArticles whose byline prints “Thomas Noll”
